BCTX
BriaCell Therapeutics Corp.
Biotechnology
Market Cap$5M
5Y Perf.-15.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BCTX vs NKTR
Revenue, margins, valuation, and 5-year total return — side by side.
NKTR
Nektar Therapeutics
Biotechnology
Market Cap$1.69B
5Y Perf.-74.4%
BCTX vs NKTR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BCTX | NKTR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $5M | $1.69B |
| Revenue (TTM) | $0.00 | $55M |
| Net Income (TTM) | $-38M | $-164M |
| Gross Margin | — | 99.6% |
| Operating Margin | — | -237.9% |
| Total Debt | $0.00 | $149M |
| Cash & Equiv. | $14M | $15M |
BCTX vs NKTR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BCTX
NKTR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BriaCell Therapeuti… (BCTX) | 100 | 84.9 | -15.1% |
| Nektar Therapeutics (NKTR) | 100 | 25.6 | -74.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BCTX vs NKTR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NKTR leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. BriaCell Therapeutics Corp. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BCTX
BriaCell Therapeutics Corp.
The Income Pick
BCTX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.56
- Lower volatility, beta 1.56, current ratio 5.01x
- Beta 1.56, current ratio 5.01x
Best for: income & stability and sleep-well-at-night
NKTR
Nektar Therapeutics
The Growth Play
NKTR carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -43.9%, EPS growth -12.1%, 3Y rev CAGR -15.7%
- -59.1% 10Y total return vs BCTX's -99.2%
- -43.9% revenue growth vs BCTX's -136.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NKTR | -43.9% revenue growth vs BCTX's -136.6% |
| Quality / Margins | BCTX | 0.4% margin vs NKTR's -297.1% |
| Stability / Safety | BCTX | Beta 1.56 vs NKTR's 1.85 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NKTR | +8.2% vs BCTX's -87.5% |
| Efficiency (ROA) | NKTR | -62.8% ROA vs BCTX's -153.6%, ROIC -57.2% vs -12.6% |
BCTX vs NKTR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
BCTX vs NKTR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNKTRLAGGINGBCTX
BCTXBriaCell Therapeutics…
1leads
NKTRNektar Therapeutics
2leads
6 Total Categories
CATEGORYLEADERvs BCTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BCTX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NKTR5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
NKTR5/5
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BCTX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NKTR and BCTX operate at a comparable scale, with $55M and $0 in trailing revenue.
| Metric | BCTXBriaCell Therapeu… | NKTRNektar Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $55M |
| EBITDAEarnings before interest/tax | -$43M | -$130M |
| Net IncomeAfter-tax profit | -$38M | -$164M |
| Free Cash FlowCash after capex | -$37M | -$209M |
| Gross MarginGross profit ÷ Revenue | — | +99.6% |
| Operating MarginEBIT ÷ Revenue | — | -2.4% |
| Net MarginNet income ÷ Revenue | — | -3.0% |
| FCF MarginFCF ÷ Revenue | — | -3.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -25.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +92.3% | -4.5% |
BCTX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BCTX and NKTR each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BCTXBriaCell Therapeu… | NKTRNektar Therapeuti… |
|---|---|---|
| Market CapShares × price | $5M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | -$9M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | -8.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 30.64x |
| Price / BookPrice ÷ Book value/share | 0.32x | 15.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BCTX and NKTR each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NKTR leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
BCTX delivers a -193.8% return on equity — every $100 of shareholder capital generates $-194 in annual profit, vs $-4 for NKTR. On the Piotroski fundamental quality scale (0–9), NKTR scores 2/9 vs BCTX's 1/9, reflecting mixed financial health.
| Metric | BCTXBriaCell Therapeu… | NKTRNektar Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -193.8% | -4.0% |
| ROA (TTM)Return on assets | -153.6% | -62.8% |
| ROICReturn on invested capital | -12.6% | -57.2% |
| ROCEReturn on capital employed | -3.4% | -55.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | — | 1.66x |
| Net DebtTotal debt minus cash | -$14M | $134M |
| Cash & Equiv.Liquid assets | $14M | $15M |
| Total DebtShort + long-term debt | $0 | $149M |
| Interest CoverageEBIT ÷ Interest expense | -796.67x | -4.74x |
NKTR leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NKTR leads this category, winning 5 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NKTR five years ago would be worth $2,765 today (with dividends reinvested), compared to $83 for BCTX. Over the past 12 months, NKTR leads with a +818.2% total return vs BCTX's -87.5%. The 3-year compound annual growth rate (CAGR) favors NKTR at 93.3% vs BCTX's -84.4% — a key indicator of consistent wealth creation.
| Metric | BCTXBriaCell Therapeu… | NKTRNektar Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -42.8% | +92.0% |
| 1-Year ReturnPast 12 months | -87.5% | +818.2% |
| 3-Year ReturnCumulative with dividends | -99.6% | +621.8% |
| 5-Year ReturnCumulative with dividends | -99.2% | -72.3% |
| 10-Year ReturnCumulative with dividends | — | -59.1% |
| CAGR (3Y)Annualised 3-year return | -84.4% | +93.3% |
NKTR leads this category, winning 5 of 5 comparable metrics.
Risk & Volatility
Evenly matched — BCTX and NKTR each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCTX is the less volatile stock with a 1.56 beta — it tends to amplify market swings less than NKTR's 1.85 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NKTR currently trades 76.5% from its 52-week high vs BCTX's 11.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BCTXBriaCell Therapeu… | NKTRNektar Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 1.85x |
| 52-Week HighHighest price in past year | $37.20 | $109.00 |
| 52-Week LowLowest price in past year | $3.60 | $7.99 |
| % of 52W HighCurrent price vs 52-week peak | +11.0% | +76.5% |
| RSI (14)Momentum oscillator 0–100 | 50.0 | 53.4 |
| Avg Volume (50D)Average daily shares traded | 185K | 991K |
Evenly matched — BCTX and NKTR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BCTXBriaCell Therapeu… | NKTRNektar Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $132.83 |
| # AnalystsCovering analysts | — | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NKTR leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). BCTX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallNektar Therapeutics (NKTR)Leads 2 of 6 categories
Loading custom metrics...
BCTX vs NKTR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BCTX or NKTR a better buy right now?
Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BCTX or NKTR?
Over the past 5 years, Nektar Therapeutics (NKTR) delivered a total return of -72.
3%, compared to -99. 2% for BriaCell Therapeutics Corp. (BCTX). Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BCTX or NKTR?
By beta (market sensitivity over 5 years), BriaCell Therapeutics Corp.
(BCTX) is the lower-risk stock at 1. 56β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 18% more volatile than BCTX relative to the S&P 500.
04Which is growing faster — BCTX or NKTR?
On earnings-per-share growth, the picture is similar: Nektar Therapeutics grew EPS -12.
1% year-over-year, compared to -44. 5% for BriaCell Therapeutics Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BCTX or NKTR?
BriaCell Therapeutics Corp.
(BCTX) is the more profitable company, earning 0. 0% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCTX leads at 0. 0% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BCTX or NKTR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BCTX or NKTR better for a retirement portfolio?
For long-horizon retirement investors, BriaCell Therapeutics Corp.
(BCTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BCTX and NKTR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.